Glaucoma

Arnica Montana, Gelsemium Sempervirens, Lycopodium Clavatum, Phosphorus, Physostigma Venenosum


Natural Ophthalmics, Inc
Human Otc Drug
NDC 68770-220
Glaucoma also known as Arnica Montana, Gelsemium Sempervirens, Lycopodium Clavatum, Phosphorus, Physostigma Venenosum is a human otc drug labeled by 'Natural Ophthalmics, Inc'. National Drug Code (NDC) number for Glaucoma is 68770-220. This drug is available in dosage form of Pellet. The names of the active, medicinal ingredients in Glaucoma drug includes Arnica Montana - 12 [hp_X]/1 Gelsemium Sempervirens Root - 6 [hp_C]/1 Lycopodium Clavatum Spore - 12 [hp_C]/1 Phosphorus - 12 [hp_X]/1 Physostigma Venenosum Seed - 12 [hp_X]/1 . The currest status of Glaucoma drug is Active.

Drug Information:

Drug NDC: 68770-220
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Glaucoma
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Arnica Montana, Gelsemium Sempervirens, Lycopodium Clavatum, Phosphorus, Physostigma Venenosum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Natural Ophthalmics, Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Pellet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ARNICA MONTANA - 12 [hp_X]/1
GELSEMIUM SEMPERVIRENS ROOT - 6 [hp_C]/1
LYCOPODIUM CLAVATUM SPORE - 12 [hp_C]/1
PHOSPHORUS - 12 [hp_X]/1
PHYSOSTIGMA VENENOSUM SEED - 12 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Apr, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 08 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Natural Ophthalmics, Inc
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:O80TY208ZW
639KR60Q1Q
C88X29Y479
27YLU75U4W
CJV9E9IIOA
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
68770-220-42600 PELLET in 1 BOTTLE (68770-220-42)27 Apr, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:


Product Elements:

Glaucoma arnica montana, gelsemium sempervirens, lycopodium clavatum, phosphorus, physostigma venenosum arnica montana arnica montana gelsemium sempervirens root gelsemium sempervirens root sucrose lycopodium clavatum spore lycopodium clavatum spore physostigma venenosum seed physostigma venenosum seed phosphorus phosphorus

Indications and Usage:

Uses: according to homeopathic indications, these ingredients offer temporary relief for the symptoms of glaucoma.†

Warnings:

Warnings: warnings: • for oral use only. if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a physician. glaucoma is a serious condition. get regular checkups from a qualified eye professional and closely monitor the progression.

Dosage and Administration:

Directions: dissolve three pellets under tongue three times per day or as directed by a medical professional.

Package Label Principal Display Panel:

Label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.